CAGRISEMA 12MG WEIGHT LOSS PEN SOUTH AFRICA – BODY PHARM
Cagrisema 12mg Pre-Filled Injectable Pen is a cutting-edge dual agonist designed to support sustainable weight loss, appetite control, and improved metabolic health. Each pen delivers 6mg of Semaglutide (GLP-1 receptor agonist)and 6mg of Cagrilintide (long-acting amylin analogue) in a convenient, once-weekly format.
Cagrisema combines two clinically researched compounds:
Together, these compounds mimic natural metabolic hormones and have been shown in studies to help participants lose up to 22.5% of their body weight.
The Cagrisema 12mg Pen features a built-in dosage selector for gradual adjustment:
This slow increase ensures optimal tolerance and effectiveness. Continue at a dosage that works well for you, as long as appetite control and weight loss progress are maintained.
Cagrisema is currently under investigation in the global REDEFINE and REIMAGINE clinical trials for weight management and type 2 diabetes. While results show strong effectiveness, it has not yet been formally approved as a combined treatment by Novo Nordisk.
Consult with a healthcare professional before starting any GLP-1 or amylin-based therapy. Not suitable for pregnant or breastfeeding individuals, or those with contraindicated conditions.
Orders are shipped across South Africa within 5–6 working days unless otherwise communicated. Due to the nature of this product and strict safety requirements, we cannot accept returns or exchanges.
With Body Pharm, you are assured of high purity peptides, precision dosing, and reliable quality. The Cagrisema 12mg Pen offers South Africans access to advanced weight management technology that works in harmony with a healthy lifestyle for lasting results.
Disclaimer: This product is investigational and intended for research and personal use under professional guidance. It is not yet approved as a standard medical treatment.